Research/Discovery
LRA Announces Inaugural Awards Promoting Diversity in Lupus Research

NEW YORK, NY, June 9, 2022. The Lupus Research Alliance (LRA), the world’s leading private funder of lupus research, today announced inaugural recipients of Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research. The Diversity in Lupus Research Award funding mechanisms aim to address underrepresentation of minorities in the scientific research profession. Lupus […] READ MORE

LRA Brings Encouraging News from European Rheumatology Meeting

June 2, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results presented at the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress from a Phase 2 trial of its investigational biologic deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib […] READ MORE

Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-class Lupus Treatment

June 1, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a Phase 2 trial of its investigational agent deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib is a potentially first-in-class inhibitor of Tyrosine kinase 2 (TYK2), which regulates […] READ MORE

Jane Salmon, MD – Determined to Help Pregnant Women Triumph Over Lupus

March 24, 2022 Recognized for her contributions to lupus during 2022’s Women’s History Month, Dr. Jane Salmon chose to specialize in lupus research because it was there that she felt she could be of greatest value.  “There were so many unknowns in lupus with all its complexity. Here was a disease primarily affecting young women […] READ MORE

Lupus Nephritis: A Major Focus at the Lupus Research Alliance

Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […] READ MORE

Catch Up on LRA News with Lupus Research Update Vol. 1, 2022

February 17, 2022 It’s with great pride that I share a sampling of the many extraordinary accomplishments of last year in our first Lupus Research Update of 2022. The Lupus Research Alliance (LRA) made important gains on many fronts—thanks to tremendous friends like you. I hope you share my pride because your support continues to be the catalyst behind every LRA accomplishment. […] READ MORE

Encouraging Results with Obinutuzumab for Lupus Nephritis

February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive results as a potential treatment for lupus nephritis in the phase 2 clinical trial NOBILITY.  A medicine designed to attach a type of blood cell called B-cells with the marker CD20 on its surface, obinutuzumab […] READ MORE

Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus Clinical Trials and Research

January 27, 2022 NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT) announced two major initiatives to address underrepresentation of minorities in clinical trials and in the scientific research profession: Project CHANGE by LT and the Diversity in Lupus Research Program. The organization has tackled these […] READ MORE

Learn and connect with our community!